Mint Markets · Finance · 2026-08-19
Moderna shares climb nearly 100% as mRNA vaccine with Merck succeeds in large trial for skin cancer
The study is ongoing, but interim results found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of keeping cancers from spreading to other parts of the body Moderna shares climb nearly 100% as mRNA vaccine with Merck succeeds in large trial for skin cancer The study is still ongoing, but interim results showed that the treatment, Intismeran, met its primary endpoint of reducing the risk of cancer recurrence
Read original on Mint Markets Get the app
Licensed summary · LicensedSummary
Related briefs
- Carvana shares are under pressure this week as Mark Walter probe fuels investor jitters
- Northrop Grumman is setting itself apart from the rest of the defense sector. How Tony Zhang is trading it
- Nvidia plays matchmaker in Nordics, sources tell CNBC, as AI data center deals boom in region
- Metal stock to be in focus on Thursday after this Capex expansion update. Details here
- US stocks bounce back as bond yields retreat